1
|
Arroyo-Andrés J, Agud-Dios M, Rubio-Muniz CA, Postigo C, Cortijo-Cascajares S, Ortiz-Romero PL. Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series. Int J Dermatol 2024; 63:e57-e59. [PMID: 38093412 DOI: 10.1111/ijd.16979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 11/26/2023] [Accepted: 12/01/2023] [Indexed: 01/19/2024]
Affiliation(s)
| | - Manuel Agud-Dios
- Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain
| | | | - Concepción Postigo
- Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain
| | | | | |
Collapse
|
2
|
Cortijo-Cascajares S, Cercós-Lletí AC, Ortiz-Pérez S, Caro-Teller JM, Ferrari-Piquero JM. Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. J Oncol Pharm Pract 2023; 29:290-298. [PMID: 34907812 DOI: 10.1177/10781552211067429] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE To study immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab, as well as to assess whether these reactions could be predictors of further effectiveness of therapy. METHODS Retrospective, observational and longitudinal study. All NSCLC patients who received nivolumab between February 2015-May 2020 were included. In terms of safety, irAEs and their severity were registered and to evaluate the effectiveness, overall survival (OS) and progression free survival (PFS) were calculated. RESULTS 75 patients were included. 32 patients (43%) were reported irAES. Mainly the irAEs affected the skin (36%). Followed by pneumonitis (20%), gastrointestinal reactions (12%), endocrine (12%) and hepatitis (12%). Regarding severity, 92% were moderate. The median PFS was 9.49 months on the group with irAEs versus 1.99 months on the group without irAEs group (p < 0.0001). The median OS was 17.44 months versus 7.67 months respectively (p = 0.0001). According to the incidence of irAEs developed ( = > 2 vs. 1 vs. 0), the median PFS was 20.53 versus 5.35 versus 1.99 months respectively (p < 0.0001). The median OS was 23.41 versus 15.80 versus 7.67 months, respectively (p = 0.0002). CONCLUSION In a significant number of patients irAEs occur, generally of grade 1-2 severity, affecting mainly the skin, lungs and gastrointestinal system. We confirm that the development of irAEs in patients with NSCLC treated with nivolumab is a strong predictor of treatment effectiveness in both PFS and OS, with statistically significant results. On those patients who experience two or more immunorelated adverse events the greatest benefit has been observed.
Collapse
Affiliation(s)
| | | | - Sara Ortiz-Pérez
- Department of Pharmacy, 16473Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | | |
Collapse
|
3
|
Arroyo-Andrés J, Agud-Dios M, Rubio-Muniz CA, Vico-Alonso C, Cortijo-Cascajares S, Ortiz-Romero PL. Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report. Int J Dermatol 2021; 61:e267-e269. [PMID: 34363613 DOI: 10.1111/ijd.15834] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2021] [Revised: 06/30/2021] [Accepted: 07/23/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Jorge Arroyo-Andrés
- Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain
| | - Manuel Agud-Dios
- Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain
| | - Carmen A Rubio-Muniz
- Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain
| | - Cristina Vico-Alonso
- Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain
| | | | - Pablo L Ortiz-Romero
- Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain
| |
Collapse
|
4
|
Jimenez RB, Vera DG, Rivera-Díaz R, Cortijo-Cascajares S, Ballesteros RM, Pastor MDCD. Successful subcutaneous desensitization in a patient with allergy to ixekizumab. The Journal of Allergy and Clinical Immunology: In Practice 2018; 6:1761-1762. [DOI: 10.1016/j.jaip.2017.12.036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 12/20/2017] [Accepted: 12/27/2017] [Indexed: 11/16/2022]
|
5
|
Martinez-Lopez J, Jimenez A, Sanchez-Calero J, Monteagudo D, Urbanowicz M, Cañamares-Orbis I, Cortijo-Cascajares S, Ayala R. Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. Ann Hematol 2015; 94:1237-9. [PMID: 25791242 DOI: 10.1007/s00277-015-2352-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 03/05/2015] [Indexed: 12/25/2022]
Affiliation(s)
- Joaquín Martinez-Lopez
- Division of Hematology, Hospital Universitario 12 de Octubre, Departamento de Medicina, Universidad Complutense, Avd de Cordoba s/n., 28041, Madrid, Spain,
| | | | | | | | | | | | | | | |
Collapse
|
6
|
García-Muñoz C, Cortijo-Cascajares S, Cañamares-Orbis I, Goyache-Goñi MP, Ferrari-Piquero JM. [Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: experience of use]. Farm Hosp 2014; 38:130-134. [PMID: 24669898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023] Open
Abstract
OBJECTIVE To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer. METHOD Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January of 2010 and May of 2012 were selected. Demographical and clinical data were gathered. RESULTS 23 patients with metastatic breast cancer (mean age 59.3 ± 13.3 years) were included. All of them had received an average of 5 treatment lines with at least one of them including Trastuzumab. The median progression-free survival rate with combined Lapatinib + Trastuzumab, with or without associated chemotherapy was 7 months (95% CI: 2.78-11.21) and 3 months for the patients only receiving Lapatinib and Trastuzumab. Seven patients experienced adverse events and in four patients the treatment was stopped due to toxicity. CONCLUSIONS The treatment with HER2-receptor inhibitors in our patients resulted in progression-free survival rates similar to those published in clinical trials with patients receiving Lapatinib + Trastuzumab not combined with any other anti-cancer therapy, with good treatment tolerability.
Collapse
Affiliation(s)
- C García-Muñoz
- Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España..
| | | | - I Cañamares-Orbis
- Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España
| | - M P Goyache-Goñi
- Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid. España
| | | |
Collapse
|
7
|
Cañamares-Orbis I, Cortijo-Cascajares S, García-Muñoz C, Goyache-Goñi MP, Ferrari-Piquero JM. [Introduction of a traceability system in the pharmacy oncology area in a tertiary hospital]. Rev Calid Asist 2014; 29:58-59. [PMID: 24440579 DOI: 10.1016/j.cali.2013.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Accepted: 04/25/2013] [Indexed: 06/03/2023]
Affiliation(s)
- I Cañamares-Orbis
- Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España.
| | | | - C García-Muñoz
- Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España
| | - M P Goyache-Goñi
- Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España
| | | |
Collapse
|
8
|
de Amuriza-Chicharro N, Gastalver-Martín C, Cortijo-Cascajares S, Ferrari-Piquero JM. [Secondary necrotizing fasciitis associated with panitumumab]. Med Clin (Barc) 2013; 141:460-1. [PMID: 23622891 DOI: 10.1016/j.medcli.2013.02.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2013] [Revised: 02/27/2013] [Accepted: 02/28/2013] [Indexed: 11/15/2022]
|
9
|
Cañamares-Orbis I, Sepúlveda-Sánchez JM, Rodríguez-Antona C, Farfan CA, García-Muñoz C, Cortijo-Cascajares S, Goyache-Goñi M, Escribano-Valenciano I. PHC-018 Pharmacogenetic Study as a Predictor of Efficacy and Toxicity in Patients with Advanced Renal Cell Carcinoma Treated with Sunitinib. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
10
|
Cortijo-Cascajares S, Nacle-López I, García-Escobar I, Aguilella-Vizcaíno MJ, Herreros-de-Tejada A, Cortés-Funes Castro H, Calleja-Hernández MÁ. Effectiveness of oxaliplatin desensitization protocols. Clin Transl Oncol 2012; 15:219-25. [DOI: 10.1007/s12094-012-0909-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2012] [Accepted: 05/28/2012] [Indexed: 10/28/2022]
|
11
|
Cortijo-Cascajares S, Jiménez-Cerezo MJ, Herreros de Tejada A. Review of hypersensitivity reactions to antineoplastic agents. Farm Hosp 2012; 36:148-58. [PMID: 22484106 DOI: 10.1016/j.farma.2011.02.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2010] [Revised: 01/19/2011] [Accepted: 02/06/2011] [Indexed: 10/28/2022] Open
Abstract
OBJECTIVE To review the characteristics and management of hypersensitivity reactions caused by antineoplastic agents. METHOD We conducted a search in the Pubmed and EMBASE databases for the last 10 years. RESULTS Almost all chemotherapeutic agents have the potential to cause hypersensitivity reactions, but some groups have been associated with increased risk, such as platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins. The clinical manifestations of these reactions are variable and unpredictable, including symptoms affecting the skin and the pulmonary, cardiac and gastrointestinal systems. The mechanism associated with their development is not yet fully understood. Diagnosis is based on patients' signs and symptoms and skin testing. The management of patients who suffer a hypersensitivity reaction to a chemotherapeutic agent varies with the severity of the reaction, the need to continue treatment, and the availability of alternative therapies. CONCLUSIONS Due to a progressive increase in the use of chemotherapeutic agents an increased incidence of hypersensitivity reactions is to be expected. Desensitisation protocols are a noteworthy alternative that make it possible to re-initiate patients' therapy with the causative agent of the hypersensitivity reaction. Their use should be assessed individually, weighing risks and benefits.
Collapse
|
12
|
Cañamares-Orbis I, Gastalver-Martin C, García-Muñoz C, Goyache-Goñi M, Cortijo-Cascajares S, de Tejada AH. Panitumumab following cetuximab: a retrospective position. Eur J Hosp Pharm 2012. [DOI: 10.1136/ejhpharm-2012-000074.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|